Skip to main content

CORRECTION article

Front. Oncol., 02 September 2021
Sec. Pharmacology of Anti-Cancer Drugs
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.740715

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China

This article is a correction to:

  1. Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China

    1. Read original article
Xiaoyan Han&#x;Xiaoyan Han1†Chunxiang Jin&#x;Chunxiang Jin1†Gaofeng ZhengGaofeng Zheng1Donghua HeDonghua He1Yi ZhaoYi Zhao1Yi LiYi Li1Wenjun WuWenjun Wu1Weiyan ZhengWeiyan Zheng1Guoqing WeiGuoqing Wei1Enfan ZhangEnfan Zhang1He HuangHe Huang1Jingsong He*&#x;Jingsong He1*‡Zhen Cai,*&#x;Zhen Cai1,2*‡
  • 1Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
  • 2Institute of Hematology, Zhejiang University, Hangzhou, China

A Corrigendum on
Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China

By Han X, Jin C, Zheng G, He D, Zhao Y, Li Y, Wu W, Zheng W, Wei G, Zhang E, Huang H, He J and Cai Z (2021). Front. Oncol. 11:665217. doi: 10.3389/fonc.2021.665217

There is an error in the title of the original article. The correct title is “Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: multiple myeloma, maintenance, proteasome inhibitors, immunomodulators, optimal maintenance duration

Citation: Han X, Jin C, Zheng G, He D, Zhao Y, Li Y, Wu W, Zheng W, Wei G, Zhang E, Huang H, He J and Cai Z (2021) Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China. Front. Oncol. 11:740715. doi: 10.3389/fonc.2021.740715

Received: 13 July 2021; Accepted: 14 July 2021;
Published: 02 September 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Han, Jin, Zheng, He, Zhao, Li, Wu, Zheng, Wei, Zhang, Huang, He and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jingsong He, hejingsong@zju.edu.cn; Zhen Cai, caiz@zju.edu.cn

†These authors have contributed equally to this work and share first authorship

‡These authors have contributed equally to this work and share the last authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.